Chart Analysis
IMU Daily Timeframe Chart as of 22 May 2026
Imugene (ASX: IMU) — Azer-cel Achieves 81% Overall Response Rate in CAR T-Naïve Blood Cancer Patients in ASCO 2026 Abstract Including 100% Response in MZL and CLL
On 22 May 2026, Imugene Limited (ASX: IMU) released clinical data from its azer-cel Phase 1b study, now published as an abstract on the American Society of Clinical Oncology (ASCO) website following the lifting of the conference embargo. Among 16 evaluable patients with relapsed or refractory blood cancers who had not previously received autologous CAR T therapy, azer-cel in combination with low-dose IL-2 achieved an overall response rate (ORR) of 81% (13 of 16 patients), with responses observed across multiple lymphoma and leukaemia subtypes including 100% response rates in marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and Waldenström macroglobulinemia (WM). Azer-cel is an allogeneic (off-the-shelf) CD19-targeting CAR T-cell therapy — a key differentiator from approved autologous CAR T products, which require individualised manufacturing from each patient's own cells. An oral presentation with an updated dataset is scheduled for 29 May 2026 at the ASCO Annual Meeting in Chicago. Imugene has also opened a new combination cohort evaluating azer-cel with a BTK inhibitor (BTKi) in patients who previously failed BTKi therapy.
Key Details at a Glance
| Detail | Value |
|---|---|
| Drug | Azer-cel (azercabtagene zapreleucel) — allogeneic CD19 CAR T-cell therapy |
| Trial Phase | Phase 1b basket study (multiple B-cell malignancies) |
| Cohort | Cohort 2 — CAR T-naïve patients |
| Patients Treated | 19 (16 evaluable for response at Day 28) |
| Overall Response Rate (ORR) | 81% (13/16 evaluable) |
| DLBCL Response Rate | 60% (1 CR, 2 PRs out of 5 evaluable) |
| MZL Response Rate | 100% (3 CRs, 1 PR out of 4 evaluable) |
| CLL Response Rate | 100% (3 PRs out of 3 evaluable) |
| FL Response Rate | 100% (1 CR out of 1 evaluable) |
| PCNSL Response Rate | 50% (1 PR out of 2 evaluable) |
| WM Response Rate | 100% (1 PR out of 1 evaluable) |
| Patient Median Age | 59 years (range 56–73) |
| ASCO Abstract | #7012 (asco.org/abstracts) |
| Oral Presentation | 29 May 2026, 1:00 PM CDT, Chicago |
| New Cohort 3 | Azer-cel + BTKi combination (including MCL indication) |
Azer-cel Phase 1b Results — Response Rates by Cancer Subtype
The abstract reports data from 19 patients enrolled in Cohort 2 (CAR T-naïve) of the ongoing Phase 1b basket study. At the data cut-off, 16 patients were evaluable for response following their first disease assessment at Day 28. Patients had relapsed or refractory B-cell malignancies and had not previously received autologous CAR T therapy. Several patients had received multiple prior therapies, including bispecific antibodies and autologous stem cell transplant.
Response rates by subtype:
| Subtype | Evaluable | ORR | Complete Responses (CR) | Partial Responses (PR) |
|---|---|---|---|---|
| DLBCL | 5 | 60% | 1 | 2 |
| MZL | 4 | 100% | 3 | 1 |
| CLL | 3 | 100% | 0 | 3 |
| PCNSL | 2 | 50% | 0 | 1 |
| FL | 1 | 100% | 1 | 0 |
| WM | 1 | 100% | 0 | 1 |
| Total | 16 | 81% | 5 | 8 |
The abstract describes encouraging response rates, robust CAR T-cell expansion, and a manageable safety profile. The full updated dataset will be presented at the oral presentation on 29 May 2026.
What is Azer-cel — Allogeneic Off-the-Shelf CAR T Therapy
Azer-cel (azercabtagene zapreleucel) is an allogeneic (off-the-shelf) CAR T-cell therapy targeting CD19 — a protein expressed on the surface of most B-cell malignancies. Unlike approved autologous CAR T products (such as Kymriah, Yescarta, Breyanzi, and Tecartus), which require harvesting each patient's own T-cells and manufacturing a personalised product over several weeks, allogeneic CAR T therapies are manufactured from donor cells in advance and can be administered to multiple patients from a single manufacturing batch.
The potential advantages of an allogeneic approach include faster patient access (no individual manufacturing wait time), lower per-patient manufacturing costs, and broader scalability. The challenges include managing host-versus-graft and graft-versus-host immune reactions, which can limit CAR T-cell persistence and efficacy. Azer-cel is administered in combination with low-dose IL-2 to support CAR T-cell expansion and persistence.
New Cohort 3 — BTKi Combination
Imugene has opened Cohort 3 in the Phase 1b protocol to evaluate azer-cel in combination with a Bruton Tyrosine Kinase inhibitor (BTKi) in patients who previously failed BTKi therapy. Mantle Cell Lymphoma (MCL) has been added as an indication. The global BTKi market reached approximately US$12.0 billion in 2025, with BTKis established as standard of care across CLL, MCL, MZL, and WM.
Market Context
IMU closed at $0.130 on the announcement day, up +35.4% from a previous close of $0.096, with the stock closing on the intraday high. The 52-week range spans $0.090 to $0.612. The ASCO Annual Meeting is the world's largest and most influential oncology conference, and abstract acceptance followed by an oral presentation slot is considered a favourable signal for the quality and relevance of clinical data. The allogeneic CAR T space has attracted significant pharmaceutical industry interest, with multiple companies pursuing off-the-shelf approaches.
Risks & Considerations
Early-stage clinical data: The results are from a Phase 1b study with 16 evaluable patients at Day 28 assessment. This is a small dataset with short follow-up. Response rates from early-phase studies with small patient numbers can change materially as more patients are enrolled and follow-up matures. Durability of responses has not been reported.
No durability data disclosed: The abstract reports response rates at Day 28 — the first assessment timepoint. Duration of response, progression-free survival, and overall survival data have not been disclosed. Responses that are not durable are of limited clinical value.
Allogeneic CAR T is unproven at scale: No allogeneic CAR T therapy has received regulatory approval globally. The approach faces fundamental biological challenges around T-cell persistence and host immune rejection. Several competitors' allogeneic programs have been discontinued or restructured due to insufficient efficacy or persistence.
Phase 1b, not pivotal: The current study is a Phase 1b basket study — an early-stage exploratory trial. Regulatory approval requires successful completion of pivotal Phase 2 or Phase 3 trials, which have not commenced. The pathway from Phase 1b to approval is typically multi-year and uncertain.
Small patient numbers per subtype: Individual subtype response rates are based on very small numbers (1–5 evaluable patients per subtype). The 100% response rates in MZL, CLL, FL, and WM are from 1–4 patients each, which is insufficient to draw conclusions about efficacy in any specific indication.
Pre-revenue company: Imugene is a clinical-stage company with no product revenue. The company requires ongoing funding to support clinical development. No financial data was disclosed in this announcement.
Competitive landscape: The CAR T and broader cell therapy space is highly competitive. Approved autologous CAR T products (Kymriah, Yescarta, Breyanzi, Tecartus) are established in the market, and multiple companies are developing allogeneic alternatives (including CRISPR Therapeutics, Caribou Biosciences, and Precision BioSciences, among others).
Key Dates & Timeline
| Date | Event |
|---|---|
| 22 May 2026 | ASCO 2026 abstract published (Abstract #7012); share price moved +35.4% |
| 29 May 2026 | Oral presentation with updated dataset at ASCO Annual Meeting, Chicago (1:00 PM CDT) |
| Recently opened | Cohort 3 — azer-cel + BTKi combination (including MCL) |
| Ongoing | Phase 1b basket study enrolment across multiple B-cell malignancies |
| TBC | Further clinical development strategy informed by basket study data |
Price Data
- Previous Close: $0.096
- Close Price (22 May 2026): $0.130
- Change (22 May 2026): +35.4%
- 52-Week Range: $0.090 – $0.612
Notable Price Levels
- $0.313 — upper range of prior trading activity
- $0.290 — earlier consolidation zone
- $0.263 — prior trading level
- $0.130 — announcement-day close and intraday high
- $0.096 — pre-announcement close
- $0.090 — near the 52-week low
Key Takeaways
- IMU moved +35.4% on 22 May 2026 following a price-sensitive ASX disclosure, closing on the intraday high of $0.130.
- The announcement — Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract — was the primary catalyst for the price movement.
- Azer-cel achieved an 81% overall response rate (13/16 evaluable) in CAR T-naïve patients with relapsed/refractory blood cancers, including 100% ORR in MZL (4 patients), CLL (3 patients), FL (1 patient), and WM (1 patient), and 60% in DLBCL (5 patients).
- Azer-cel is an allogeneic (off-the-shelf) CD19 CAR T therapy — no allogeneic CAR T has received regulatory approval globally. The data is from a Phase 1b study with 16 evaluable patients at Day 28 assessment.
- An oral presentation with updated data is scheduled for 29 May 2026 at ASCO in Chicago. A new BTKi combination cohort (Cohort 3, including MCL) has been opened.
- Response durability, progression-free survival, and overall survival have not been reported. Individual subtype response rates are based on 1–5 patients each.
Summary
Imugene released Phase 1b data showing its allogeneic CAR T therapy azer-cel achieved an 81% overall response rate in 16 evaluable CAR T-naïve patients with relapsed or refractory blood cancers, with responses across six B-cell malignancy subtypes including 100% ORR in MZL, CLL, FL, and WM. The data was published as ASCO Abstract #7012 following the lifting of the conference embargo and coincided with a +35.4% move to $0.130. An oral presentation with an updated dataset is scheduled for 29 May 2026 at the ASCO Annual Meeting in Chicago. The results are from an early-phase basket study with small patient numbers per subtype (1–5 evaluable) and Day 28 follow-up only — response durability has not been reported. No allogeneic CAR T therapy has received regulatory approval globally, and the pathway from Phase 1b to approval is multi-year. Imugene has opened a new cohort evaluating azer-cel in combination with a BTK inhibitor for patients who previously failed BTKi therapy, with MCL added as an indication.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.